Fiche publication
Date publication
juin 2018
Journal
Journal of medical case reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
,
Pr BROSEUS Julien
,
Dr D'AVENI-PINEY Maud
Tous les auteurs :
D'Aveni-Piney M, Divoux M, Busby-Venner H, Muller M, Broséus J, Feugier P
Lien Pubmed
Résumé
Waldenström's macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström's macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but not idelalisib) is currently approved for treatment of patients with relapsed or refractory Waldenström's macroglobulinemia.
Mots clés
Anuric renal failure, Idelalisib, Waldenström’s macroglobulinemia
Référence
J Med Case Rep. 2018 Jun 12;12(1):164
